Date: 2014-06-25
Type of information: R&D agreement
Compound: XR-17
Company: Oasmia Pharmaceutical (Sweden) global pharmaceutical company
Therapeutic area:
Type agreement: R&D
Action mechanism: XR-17 is a patented, nanoparticle formulation technology, which makes single or multiple APIs water soluble. XR-17, which consist of Vitamin A derivatives forms structures called micelles with the encapsulated active substance. A micelle containing a water insoluble substance consists of the active ingredient surrounded by XR-17 with the hydrophobic, non-polar chain pointing towards the active ingredient and the hydrophilic, polar head pointing outwards. If the active compound is water soluble, the hydrophilic, polar head points inwards. The micelles are extremely small, 20 to 60 nm depending on the API, and quality as nanoparticles. The toxicity of, XR-17 is low. Animal data indicate that a dose eight times the expected dose used in formulation in clinical trials is non-toxic.
Disease:
Details: * On June 25, 2014, Oasmia Pharmaceutical announced that a research agreement has been signed between Oasmia and a global pharmaceutical company. The agreement relates to the use of Oasmia’s patented nanoparticle formulation technology XR-17. The full terms of the agreement cannot be disclosed at this point in time. Under the terms of the agreement, Oasmia will initially perform tests to investigate the possibility of making a solid formulation with the partner\'s specified compound in combination with XR-17. XR-17 has been proven in several pre-clinical and clinical studies to make single or multiple APIs (Active Pharmaceutical Ingredients) water-soluble. If the results of these tests are considered promising according to the terms of the agreement, further development work will continue in collaboration with the partner at their research facilities. The XR-17 technology is the basis for Oasmia\'s own project portfolio within human and veterinary oncology which consists of one conditionally approved product, (Paccal Vet®-CA1), one in registration (Paclical), and a further four products in various phases of clinical studies and pre-clinical development.
Financial terms:
Latest news:
